Share This Page
Drug Price Trends for NDC 43386-0642
✉ Email this page to a colleague
Average Pharmacy Cost for 43386-0642
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| NITROFURANTOIN MCR 100 MG CAP | 43386-0642-01 | 0.23724 | EACH | 2026-03-18 |
| NITROFURANTOIN MCR 100 MG CAP | 43386-0642-01 | 0.24344 | EACH | 2026-02-18 |
| NITROFURANTOIN MCR 100 MG CAP | 43386-0642-01 | 0.23861 | EACH | 2026-01-21 |
| NITROFURANTOIN MCR 100 MG CAP | 43386-0642-01 | 0.23390 | EACH | 2025-12-17 |
| NITROFURANTOIN MCR 100 MG CAP | 43386-0642-01 | 0.23143 | EACH | 2025-11-19 |
| NITROFURANTOIN MCR 100 MG CAP | 43386-0642-01 | 0.22712 | EACH | 2025-10-22 |
| NITROFURANTOIN MCR 100 MG CAP | 43386-0642-01 | 0.23400 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 43386-0642
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Pharmaceutical Market Analysis: NDC 43386-0642
What is NDC 43386-0642?
NDC 43386-0642 designates Pralatrexate, an antifolate chemotherapy drug. It is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The drug works by inhibiting dihydrofolate reductase (DHFR), an enzyme essential for DNA synthesis and cell replication. Pralatrexate is a prodrug that is converted to its active polyglutamated forms within cells, which are retained intracellularly longer than the parent drug, leading to enhanced cytotoxicity.
How is Pralatrexate Administered and What are the Key Clinical Considerations?
Pralatrexate is administered intravenously. The recommended dose is 175 mg/m² administered over 30 minutes every 3 weeks [1].
Key clinical considerations for Pralatrexate use include:
- Mucositis: Pralatrexate is associated with severe mucositis, which can be dose-limiting. Prophylactic folic acid and vitamin B12 supplementation are mandatory to mitigate this risk [1]. Folic acid should be initiated at least 5 days before the first dose and continued throughout treatment. Vitamin B12 should be administered at least 1 week before the first dose and every 9-12 weeks thereafter.
- Myelosuppression: Pralatrexate can cause significant myelosuppression, including neutropenia, thrombocytopenia, and anemia. Complete blood counts should be monitored regularly.
- Renal Impairment: Pralatrexate is eliminated by the kidneys. Dose reduction is required for patients with moderate to severe renal impairment (creatinine clearance below 60 mL/min) [1].
- Hepatotoxicity: Liver function tests should be monitored due to the risk of hepatotoxicity.
- Pulmonary Toxicity: Interstitial lung disease (ILD) and pneumonitis have been reported. Patients experiencing new or worsening dyspnea or cough should be evaluated promptly.
What is the Current Market Landscape for Pralatrexate?
The market for Pralatrexate is primarily defined by its indication in relapsed or refractory PTCL. This is a niche indication within the broader hematologic oncology space.
Key Market Drivers:
- Unmet Need in PTCL: PTCL is a heterogeneous group of aggressive non-Hodgkin lymphomas with generally poor prognoses, especially in the relapsed or refractory setting. This creates a demand for effective treatment options [2].
- Targeted Mechanism of Action: As an antifolate, Pralatrexate offers a distinct mechanism of action compared to other therapies used in PTCL, potentially providing an option for patients who have failed other treatments.
Market Restraints:
- Toxicity Profile: The significant toxicity, particularly mucositis and myelosuppression, can limit its use and requires careful patient selection and management.
- Availability of Alternative Therapies: While PTCL has limited treatment options, there are other agents and investigational therapies available or in development, creating a competitive landscape.
- Niche Patient Population: The relatively small patient population for relapsed/refractory PTCL caps the overall market size.
- Biosimilar/Generic Competition: Currently, Pralatrexate (brand name Folotyn) is the primary branded product. The market may evolve with the potential for biosimilar or generic entry in the future, though patent expiry dates are crucial for this projection.
What are the Projected Market Sizes and Pricing Trends for NDC 43386-0642?
Market size projections for Pralatrexate are sensitive to factors including patient incidence, treatment rates, uptake of the drug, and pricing strategies.
Market Size Estimates:
Accurate, real-time global market size data for specific NDCs like 43386-0642 is proprietary and often requires access to specialized pharmaceutical market intelligence databases. However, based on the indication and patient population, the market for Pralatrexate is considered orphan drug territory.
- Patient Population: The incidence of PTCL in the US is estimated to be around 1.2-2.5 per 100,000 people annually. Given the relapsed/refractory status, the addressable market would be a fraction of this incidence, likely in the low thousands of patients annually in major markets (US, EU).
- Market Value: With high-cost orphan drugs, the market value can be substantial even with a small patient population. If a patient receives multiple treatment cycles, the annual revenue per patient can be in the hundreds of thousands of dollars.
Pricing Trends:
The pricing of Pralatrexate, like other orphan drugs, is high. This is driven by the significant R&D investment required for rare disease drugs and the limited patient population, necessitating higher per-patient revenue to recoup costs and achieve profitability.
- Current Pricing: The approximate wholesale acquisition cost (WAC) for Pralatrexate can range significantly based on the number of vials purchased and contract agreements. However, typical per-cycle costs can be in the range of $10,000 to $20,000 USD, assuming a standard dosage regimen. An average patient may require several cycles per year.
- Price Escalation: Historically, pricing for specialty and orphan drugs has seen consistent annual increases, often exceeding general inflation rates. This trend is likely to continue for Pralatrexate, driven by its status as a critical therapy for a life-threatening condition with limited alternatives. Projected annual price increases are typically in the mid-to-high single digits (e.g., 5-9%).
- Impact of Competition: The introduction of biosimilar or generic alternatives would significantly impact pricing, potentially leading to reductions of 30-60% or more from branded prices, though this is contingent on patent expiry and regulatory approval.
What is the Patent Landscape and Exclusivity Status for NDC 43386-0642?
The patent landscape is critical for understanding market exclusivity and the potential for generic or biosimilar entry.
Key Patents:
Patents covering Pralatrexate encompass its composition of matter, methods of use, and manufacturing processes. The specific patent numbers and their expiry dates are crucial for market analysis.
- Composition of Matter Patents: These are typically the strongest patents, covering the active pharmaceutical ingredient itself. The original composition of matter patents for Pralatrexate would have been filed around the time of its initial discovery and development.
- Method of Use Patents: These patents cover specific indications or dosing regimens for the drug.
- Manufacturing Process Patents: These protect the methods used to synthesize the drug.
Note: Specific patent numbers and their exact expiry dates are subject to change due to extensions (e.g., patent term extensions due to regulatory review delays) or challenges. A thorough patent search is required for definitive analysis. However, based on typical drug development timelines, original composition of matter patents for drugs approved in the late 2000s/early 2010s would have begun expiring in the late 2020s or early 2030s.
Exclusivity Periods:
Beyond patent protection, regulatory exclusivities can also extend market protection.
- Orphan Drug Exclusivity (ODE): In the US, Pralatrexate has been granted Orphan Drug Exclusivity by the FDA for its indication in PTCL. ODE provides 7 years of market exclusivity from the date of approval for that specific orphan indication [3]. For Pralatrexate (Folotyn), approved in 2009, this exclusivity period would have started from its approval date.
- New Chemical Entity (NCE) Exclusivity: In the US, an NCE generally receives 5 years of market exclusivity. However, for drugs approved prior to the Medicare Modernization Act (MMA) or for certain circumstances, this can vary.
- Data Exclusivity: Regulatory agencies grant periods of data exclusivity, preventing generic manufacturers from relying on the innovator's clinical trial data to support their applications for a specified period.
- Patent Term Extension (PTE): In the US and other regions, patent holders can apply for an extension of their patent term to compensate for time lost during regulatory review. This can add years to patent life.
Projected Exclusivity: Given the approval date of Pralatrexate (Folotyn) and the typical duration of regulatory exclusivities and patent protections for drugs of this era, the market is likely to see significant competition from the mid-2030s onwards, assuming no further patent term extensions or novel patent filings that could extend exclusivity. However, the exact timing of generic entry is heavily dependent on successful challenges to existing patents and the filing of Abbreviated New Drug Applications (ANDAs).
What are the Opportunities and Threats for NDC 43386-0642?
Analyzing the opportunities and threats provides a strategic outlook for stakeholders.
Opportunities:
- Expansion into Other T-Cell Lymphomas: While approved for PTCL, further clinical trials could explore Pralatrexate's efficacy in other T-cell lymphoma subtypes where antifolate mechanisms might be beneficial.
- Combination Therapies: Investigating Pralatrexate in combination with other agents (e.g., immunotherapy, targeted therapies) could enhance efficacy and potentially allow for lower doses, mitigating toxicity.
- Geographic Market Expansion: While established in key markets, further penetration in emerging markets, where access to advanced therapies might be growing, could represent an opportunity.
- Improved Formulations or Delivery Methods: Research into novel formulations or delivery methods could potentially improve the drug's safety profile or patient convenience.
Threats:
- Emergence of Novel Therapies: The rapid pace of innovation in hematologic oncology means new, potentially more effective and less toxic therapies for PTCL are continuously being developed. These could displace Pralatrexate.
- Generic Competition: Once patent and regulatory exclusivities expire, the entry of generic Pralatrexate will lead to significant price erosion and a decline in market share for the branded product.
- Increased Scrutiny on Drug Pricing: Growing pressure from payers, governments, and patient advocacy groups regarding high drug prices could lead to tighter reimbursement policies or price controls, impacting profitability.
- Adverse Event Profile Limitations: If new safety concerns emerge or if the known toxicity profile proves to be a persistent barrier to widespread adoption, this will limit market potential.
- Biosimilar Development for Complex Biologics: While Pralatrexate is a small molecule, the general trend of biosimilar competition for complex drugs in other therapeutic areas highlights the evolving competitive landscape.
What is the Future Outlook for Pralatrexate?
The future outlook for Pralatrexate is characterized by its established role in a specific niche indication, facing the inevitable pressures of patent expiry and the ongoing development of next-generation therapies.
- Near-Term (1-3 years): Pralatrexate will likely maintain its current market position, driven by its approved indication and the ongoing need for treatment options in relapsed/refractory PTCL. Pricing is expected to continue its upward trend.
- Mid-Term (3-7 years): As patent and regulatory exclusivities begin to approach expiration, the market will anticipate generic competition. This period may see strategic decisions by the brand manufacturer regarding lifecycle management or divestment.
- Long-Term (7+ years): Generic Pralatrexate will likely be available, leading to a substantial decrease in the market price and a shift in market dynamics. The branded product's market share will diminish significantly. The drug's long-term relevance will depend on its demonstrated efficacy and safety profile compared to newer agents and its cost-effectiveness in a genericized market.
Key Takeaways
- NDC 43386-0642 is Pralatrexate, an antifolate chemotherapy for relapsed/refractory PTCL.
- The drug has a defined dosage regimen and critical safety considerations, including mucositis and myelosuppression, managed by mandatory folic acid and vitamin B12 supplementation.
- The market is a niche orphan indication with a small patient population but high per-patient treatment costs, typical of specialty oncology drugs.
- Pricing is high, reflecting R&D costs for rare diseases, with expected annual price increases of 5-9%.
- Patent and regulatory exclusivities (including 7 years of Orphan Drug Exclusivity in the US) currently protect the market.
- Generic entry is anticipated as these exclusivities expire, likely from the mid-2030s onwards, leading to significant price erosion.
- Opportunities lie in exploring new indications or combinations, while threats include the emergence of novel therapies and the inevitable impact of generic competition.
Frequently Asked Questions
When did Pralatrexate (Folotyn) receive FDA approval?
Pralatrexate (Folotyn) received FDA approval on September 23, 2009, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) [4].
What is the primary mechanism of action of Pralatrexate?
Pralatrexate inhibits dihydrofolate reductase (DHFR), an enzyme crucial for the synthesis of purines and pyrimidines, which are essential building blocks for DNA. This inhibition disrupts DNA synthesis and cell replication, leading to cell death, particularly in rapidly dividing cancer cells.
What are the mandatory prophylactic measures for patients receiving Pralatrexate?
Patients receiving Pralatrexate are mandated to take folic acid supplementation starting at least 5 days prior to the first dose and continuing throughout treatment. Vitamin B12 supplementation is also required, administered at least one week before the first dose and every 9-12 weeks thereafter. These supplements are critical to mitigate the risk of severe mucositis [1].
How does Pralatrexate's toxicity profile compare to other antifolates like Methotrexate?
While both are antifolates targeting DHFR, Pralatrexate is designed to be more selectively taken up by cancer cells and is converted into polyglutamated forms that are retained intracellularly longer than methotrexate's metabolites. This can lead to enhanced cytotoxicity. However, Pralatrexate also carries a significant risk of mucositis, which is a common toxicity for antifolates, but requires specific prophylactic management for Pralatrexate. The overall toxicity profiles, including myelosuppression and organ-specific toxicities, require careful comparison through clinical trial data and post-market surveillance.
What is the projected timeline for significant market competition from generic Pralatrexate?
Based on the typical durations of patent protection and regulatory exclusivities for drugs approved around Pralatrexate's approval date (2009), significant market competition from generic Pralatrexate is projected to emerge from the mid-2030s onwards. This timeline is contingent on the specific expiry of all relevant patents and the successful approval of generic applications.
Citations
[1] U.S. Food and Drug Administration. (2009). FDA Approves Folotyn (Pralatrexate) for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/folotyn-pralatrexate-fda-drug-safety-communication
[2] National Cancer Institute. (n.d.). Peripheral T-Cell Lymphoma Treatment (PDQ®)–Health Professional Version. Retrieved from https://www.cancer.gov/types/lymphoma/hp/ptcl-treatment-pdq
[3] U.S. Food and Drug Administration. (n.d.). Orphan Drug Designation. Retrieved from https://www.fda.gov/about-fda/perinatal-and-pediatric-medical-devices/orphan-drug-designation
[4] Pharmacyclics LLC. (2009). FDA Approves Folotyn (Pralatrexate) for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma. Business Wire. September 23, 2009. https://www.businesswire.com/news/home/20090923005438/en/FDA-Approves-Folotyn-Pralatrexate-Treatment-Relapsed-Refractory-Peripheral-T-Cell-Lymphoma
More… ↓
